Barclays’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
Other funds holding INFI
BI
SFM
CC
E
Barclays's INFI Position: Q1 2023 in Review
Barclays sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 359 shares — an estimated $199 sold.
Barclays first reported a position in INFI in Q2 2013 and held it in 33 quarters. The position peaked at $3.98M in Q3 2014. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.
- Barclays reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Barclays sold 359 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $199.
- Barclays first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
- Barclays's Infinity Pharmaceuticals, Inc. position peaked at $3.98M in Q3 2014.
- 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.
Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.